Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer
December 2nd, 2020
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure”) is pleased today to announce the appointment of Kelsey Ramsden as President and Chief Executive Officer, effective immediately. With Over 15 years founding, scaling and operating innovative businesses across several industries, Mrs. Ramsden has built multiple eight-figure companies from the ground up. She is an experienced leader and acclaimed entrepreneur, twice recognized as Canada’s Top Female Entrepreneur of the Year. After serving as Mind Cure’s COO, Mrs. Ramsden steps into the President and CEO role as of December 1, 2020. She possesses a thorough understanding of the mental health industry and a clear vision of where it is going.
Mrs. Ramsden stated, “I am humbled and excited to step into the position of President and CEO at Mind Cure. I have a profound passion for this industry and finding a better way to treat mental health. Through firsthand experience I know the incredibly promising potential of new drugs, treatments and therapies and am excited to work with our team to bring them to people in need.”
After guiding Mind Cure through its initial public offering and early operations, former President and CEO Philip Tapley will continue to serve the Board of Directors as Chairman. It was obvious to him early on that Mrs. Ramsden was the right leader to continue to build upon what he started. “Mrs. Ramsden will take our strategic vision to new heights,” said Mr. Tapley. “We have earned the trust of the industry and our shareholders these past few months, and now we get to work to translate that into earning the trust of our customers and those in need of new mental health treatments. Mrs. Ramsden has the full support of our Board of Directors and the right strategic plan in place for Mind Cure to become an industry leader.”
Mind Cure aims to identify and develop the pathways transforming mental health and wellness. Its unique focus will provide doctors, clinicians, and health regulators with data-driven research to prove the efficacy of treatment for people suffering from mental health illnesses and looking for a new way forward. “There are many promising companies, areas of research and studies emerging every single day in our industry. I will ensure that everything we do at Mind Cure is built on trust and backed by science,” said Mrs. Ramsden. “This growing industry of psychedelics and new mental health treatments requires a paradigm shift away from the old way of doing things. I have done things differently as a leader throughout my career. This industry needs more individualization. Richer scientific rigor. More empathy and trust that is earned. This is how I plan to lead Mind Cure.”
About Mrs. Ramsden
Kelsey Ramsden has spent her life building and scaling businesses in unconventional ways. She was named one of Canada’s 100 most powerful women, won Canada’s #1 female entrepreneur two years in a row, and proudly serves as a Richard Branson Centre Mentor.
Mrs. Ramsden also serves on the Entrepreneurship Council for the University of Western Ontario. An accomplished keynote speaker and bestselling author, she holds an MBA from the Richard Ivey School of Business at the University of Western Ontario.
The Company has granted a total of 500,000 stock options to Mrs. Ramsden pursuant to the terms of her executive employment agreement and the Company’s incentive stock option plan (the “Plan”). The stock options are exercisable at a price of $0.63 and subject to the terms of the Plan.
About Mind Cure Health Inc.
Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.
Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.